Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is a key signaling hub at the intersection of cell survival, apoptosis, and necroptosis pathways. Upon tumor necrosis factor receptor 1 (TNFR1) activation, RIPK1 scaffolds signaling complexes that determine cell fate: NF-κB activation and survival, caspase-8-mediated apoptosis, or RIPK3/MLKL-dependent necroptosis. [1]
In neurodegenerative diseases, RIPK1-mediated necroptosis contributes to neuronal death, neuroinflammation, and disease progression. RIPK1 inhibitors represent a promising therapeutic strategy for Alzheimer's disease, Parkinson's disease, ALS, and multiple sclerosis. [2]
RIPK1 contains:
Upon TNF-α binding, TNFR1 recruits:
RIPK1 ubiquitination by cIAPs creates a platform for NF-κB activation, promoting survival and inflammatory gene expression. [3]
When ubiquitination fails, RIPK1 can initiate either:
RIPK1-mediated necroptosis contributes to AD: [4]
RIPK1 involvement in PD: [5]
| Drug | Status | Application |
|---|---|---|
| Necrostatin-1 | Research tool | Preclinical |
| GSK2982772 | Phase I complete | Inflammatory diseases |
| GSK3145096 | Clinical trials | Autoimmune |